•The requirement for ICOS expression confirmation by IHC in pre-treatment biopsies prior to start of treatment was removed. •The protocol was modified to require tetanus booster administration 3-7 days prior to first treatment. •The protocol was modified to optimize sample collection for pharmacokinetic, pharmacodynamic analysis.